NPR Top Stories
![]() |
Good morning. BRITTNEY MELTON UP FIRST NEWSLETTER WRITER NPR |
Today’s top stories |
|
Andrew Harnik/Getty Images |
The Trump administration has signed a nuclear cooperation agreement with Saudi Arabia that would allow American companies to operate commercial nuclear power plants in the country. American companies will have priority access to supply nuclear reactors and fuel to the Saudi nuclear energy program, according to an administration memo about the agreement seen by NPR. Saudi Arabia cannot reprocess American nuclear material for weapons per the agreement. But the memo lacks the "gold standard" provisions that would prevent the country from using American-built plants to enrich uranium or other nuclear fuel supplied by other countries. The country is also not required to adopt terms that would lead to greater oversight from the International Atomic Energy Agency. |
|
House Republicans passed several significant pieces of legislation yesterday ahead of a more than month-long recess. Lawmakers approved $1.1 trillion for the National Defense Authorization Act (NDAA), with six Democrats joining Republicans in supporting the effort. Republicans also separately advanced a $95 billion budget blueprint that would set them up for a reconciliation bill. The framework allocates more than $70 billion for the war in Iran, $12 billion for farmers and funds to implement the SAVE America Act, President Trump’s election overhaul bill. The House also advanced a bill that could ban lawmakers from acquiring new individual stocks while in office, and voted to extend government funding past the midterms to Dec. 4. These bills are now headed to the Senate, which will be in session for one more week. |
|
Starting today, the Food and Drug Administration is holding a two-day meeting to decide whether compounding pharmacies should be allowed to produce popular injectable peptides. The panel will evaluate seven compounds, including the highly sought-after TB-500, BPC-157 and MOTs-C. These compounds have not undergone large-scale trials to assess safety and effectiveness, which the FDA requires for drug approval. Despite limited data, many in the wellness industry tout peptides for claims related to recovery, muscle growth, fat loss and more. Despite limited data, some major direct-to-consumer telehealth companies, med spas and high-end longevity medical practices market peptides for their potential to assist with recovery, muscle growth, fat loss and more. Others argue that the current Biden-era restrictions are pushing consumers toward unregulated overseas suppliers, increasing safety risks. |
An independent autopsy of 18-year-old Nolan Wells failed to reveal a clear cause of death, prominent civil rights attorney Benjamin Crump announced yesterday. "These findings are inconclusive ... pending further investigation," Crump said during a press conference. He added that the body wasn't in a suitable condition for a complete forensic examination. Wells was found dead two days after the Fourth of July on an island off the Mississippi coast after attending a party with friends. The press conference aimed to urge law enforcement to accelerate their efforts, as the public's concerns linger about the possibility of foul play and the role of race in Wells' death. |



Comments